Evidence map›Paper›PMID 42404299›Full record

ArticleClinical and translational radiation oncology2026

Exploration of the radiation dose-toxicity relationship for multiple ophthalmological organs at risk for pediatric patients assessed in long-term head and neck rhabdomyosarcoma survivors.

Michèle Morfouace, Marinka Hol, Reineke Schoot, Natalia Arruti, Jan Wiersma, Mark Gaze, Henry Mandeville, Olga Slater, Eric Sandler, Raquel Dávila-Fajardo and 8 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michèle MorfouacePrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Marinka HolPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Reineke SchootPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Natalia ArrutiDepartment of Otology and Orbital Surgery, Great Ormond Street Hospital, London, United Kingdom.
Jan WiersmaDepartment of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, the Netherlands.
Mark GazeDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Henry MandevilleDepartment of Radiotherapy, The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom.
Olga SlaterDepartment of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Eric SandlerDivision of Hematology and Oncology, Nemours Children's Health, Jacksonville, FL, United States.
Raquel Dávila-FajardoPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Julie BradleyDepartment of Radiation Oncology, University of Florida, Jacksonville, FL, United States.
Bradley PietersDepartment of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, the Netherlands.
Matumba KayembeDepartment of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Johannes MerksPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Ludwig SmeelePrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Peerooz SaeedOrbital centre, department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Arjan BelDepartment of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, the Netherlands.
Daniel IndelicatoDepartment of Radiation Oncology, University of Florida, Jacksonville, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Ophthalmological adverse events (OAE) are prevalent after local treatment for pediatric head and neck rhabdomyosarcoma (HNRMS). We examine the relation between radiation dose to multiple ophthalmological organs at risk (OAR) and associated clinical OAE in HNRMS survivors. Methods: Clinical data on OAE were systematically assessed in an international cross-sectional cohort study including survivors of primary pediatric HNRMS with ≥ 2 years follow-up. Included survivors were treated with either external beam radiation therapy with photons (XRT) or protons (PBT), or with brachytherapy (BT). BT was always delivered in conjunction with surgery (AMORE strategy), whereas XRT and PBT were sometimes combined with surgery. Dosimetric data were collected from the original radiotherapy treatment plans. OAR were delineated on the 3D radiotherapy planning CT. Radiation dose was recalculated into the equivalent dose in 2 Gy fractions (GyEQD2). Results: A total of 74 eyes in 38 survivors were assessed. Median follow-up time was 9 years. Following mean doses > 40, >10, and > 6 GyEQD2 to the orbit, lacrimal gland, and lens, respectively, survivors had a > 20% probability of globe displacement, dry eyes, or cataract (any grade) at follow-up. Retinopathy and optic neuropathy only occurred following maximum doses of > 40 and > 53 GyEQD2 to the retina and optic nerve, respectively. Conclusion: We offer the first description of specific dose-toxicity relationship for multiple OAR in children, based on clinically assessed OAE in long-term survivors. These results can help to quantify and inform physicians and future patients about expected probability of clinical toxicity and help to avoid OAE occurrence for future patients.

Indexed as

Cancer survivorsChildDose-response relationship, radiationEye diseasesRadiotherapyRhabdomyosarcoma

Identifiers

PMID42404299
PMCPMC13330630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.